Cargando…

Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures

Polymyxin B is the last line of defense in treating multidrug-resistant gram-negative bacterial infections. Dosing of polymyxin B is currently based on total body weight, and a substantial intersubject variability has been reported. We evaluated the performance of different population pharmacokineti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tam, Vincent H., Lee, Lawrence S., Ng, Tat-Ming, Lim, Tze-Peng, Cherng, Benjamin P. Z., Adewusi, Hafeez, Hee, Kim H., Ding, Ying, Chung, Shimin Jasmine, Ling, Li-Min, Chlebicki, Piotr, Kwa, Andrea L. H., Lye, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698783/ https://www.ncbi.nlm.nih.gov/pubmed/33217914 http://dx.doi.org/10.3390/microorganisms8111814

Ejemplares similares

Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study
por: Cai, Yiying, et al.
Publicado: (2020)

Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients
por: Hanafin, Patrick O., et al.
Publicado: (2021)

1269. Prospective Evaluation of a Machine Learning Model that Guides Indication for Antibiotics in Lower Respiratory Tract Infections
por: Tang, Sarah, et al.
Publicado: (2023)

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
por: Zhou, Yvonne Peijun, et al.
Publicado: (2014)

A Review of the Clinical Pharmacokinetics of Polymyxin B
por: Avedissian, Sean N., et al.
Publicado: (2019)

564. A Five-Year Evolutionary Study of the Minimum Inhibitory Concentrations of Methicillin-resistant Staphylococcus aureus to Mupirocin, Chlorhexidine, and Octenidine in a Singaporean Tertiary Institution
por: Zheng, Shuwei, et al.
Publicado: (2019)

In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore
por: Lim, Tze-Peng, et al.
Publicado: (2011)

163. Can Machine Learning Guide Antibiotic Initiation for Lower Respiratory Tract Infections?
por: Tang, Sarah, et al.
Publicado: (2023)

Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
por: Lim, Tze-Peng, et al.
Publicado: (2011)

Population pharmacokinetics of polymyxin B: a systematic review
por: Chen, Na, et al.
Publicado: (2022)

Hospital Pharmacists and Antimicrobial Stewardship: A Qualitative Analysis
por: Wong, Lok Hang, et al.
Publicado: (2021)

Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations
por: Teo, Jocelyn, et al.
Publicado: (2015)

2542. Attenuation of Polymyxin and Aminoglycoside-Associated Nephrotoxicity
por: Hudson, Cole, et al.
Publicado: (2023)

708. Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients
por: Tang, Sarah Si Lin, et al.
Publicado: (2018)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
por: Li, Ying, et al.
Publicado: (2021)

1079. Impact of Antimicrobial Stewardship Program (ASP) on Patients with Neurological Conditions
por: Hoon Andrea Kwa, Lay, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models
por: van der Meijden, Aart, et al.
Publicado: (2023)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
por: Wang, Peile, et al.
Publicado: (2021)

Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients
por: Liang, Danhong, et al.
Publicado: (2023)

An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis
por: Lee, Winnie, et al.
Publicado: (2014)

Antibiotic utilisation and resistance over the first decade of nationally funded antimicrobial stewardship programmes in Singapore acute-care hospitals
por: Ng, Tat Ming, et al.
Publicado: (2023)

Impact of Antimicrobial Stewardship Program (ASP) on Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in an Acute-Tertiary Care Hospital
por: Loo, Li Wen, et al.
Publicado: (2015)

187. Comparison of Active Versus Passive Strategies in Improving Compliance to Antimicrobial Stewardship Interventions
por: Tang, Sarah Si Lin, et al.
Publicado: (2018)

Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206
por: Bruss, Jon, et al.
Publicado: (2021)

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
por: Yu, Zhenwei, et al.
Publicado: (2022)

The Difference Between Polymyxin B and Polymyxin E in Causing Skin Hyerpigmentation
por: Zou, Dongna, et al.
Publicado: (2021)

2278. The Safety of Aztreonam vs. Ceftazidime in Patients with Penicillin Allergy: A Matched Cohort Study
por: Tan, Jun Jie, et al.
Publicado: (2023)

213 Impact of Antimicrobial Stewardship Strategies on Antimicrobial Use: A Systematic Review
por: Zhou, Yvonne Peijun, et al.
Publicado: (2014)

228. Impact of Early Alert to Antimicrobial Stewardship Interventions with the Prospective Audit and Feedback Strategy
por: Tang, Sarah Si Lin, et al.
Publicado: (2018)

Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19)
por: Liew, Yixin, et al.
Publicado: (2020)

Polymyxins: To Combine or Not to Combine?
por: Perez, Federico, et al.
Publicado: (2019)

Apheresis of activated leukocytes with an immobilized polymyxin B filter
por: Takeyama, N, et al.
Publicado: (2010)

Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B
por: Gallardo-Godoy, Alejandra, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Overview of polymyxin resistance in Enterobacteriaceae
por: da Silva, Kesia Esther, et al.
Publicado: (2022)

More effective use of polymyxin-B hemoperfusion for nonoperation cases
por: Yahata, M, et al.
Publicado: (2014)

Polymyxin B Etest Fails to Distinguish Carbapenem-resistant Enterobacteriaceae with Elevated Polymyxin B MICs
por: Kulengowski, Brandon, et al.
Publicado: (2017)

RapidResa Polymyxin Acinetobacter NP(®) Test for Rapid Detection of Polymyxin Resistance in Acinetobacter baumannii
por: Bouvier, Maxime, et al.
Publicado: (2021)

Difficulty in detecting low levels of polymyxin resistance in clinical Klebsiella pneumoniae isolates: evaluation of Rapid Polymyxin NP test, Colispot Test and SuperPolymyxin medium
por: Conceição-Neto, O.C., et al.
Publicado: (2020)

Transcriptional responses of Burkholderia cenocepacia to polymyxin B in isogenic strains with diverse polymyxin B resistance phenotypes
por: Loutet, Slade A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tn9e0hk4i7l6f3fr5fe9iaf77v